Title |
Agomelatine as monotherapy for major depression: an outpatient, open-label study
|
---|---|
Published in |
Neuropsychiatric Disease and Treatment, October 2013
|
DOI | 10.2147/ndt.s49062 |
Pubmed ID | |
Authors |
Jan Pecenak, Vladimir Novotny |
Abstract |
Agomelatine is a novel antidepressant agonist to MT1 and MT2 subtypes of melatoninergic receptors (MT1 and MT2) and antagonist to 5-HT2C subtype of serotonergic (5-HT2C) receptors, which has shown antidepressant efficacy in short-term and long-term trials as well as in clinical practice. The purpose of this study was to assess the antidepressant efficacy, safety, and the influence of agomelatine on the functioning of patient in common clinical practice. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 33% |
Unknown | 2 | 67% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 2 | 67% |
Members of the public | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 32 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 32 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 6 | 19% |
Student > Bachelor | 4 | 13% |
Student > Ph. D. Student | 4 | 13% |
Student > Doctoral Student | 2 | 6% |
Professor | 2 | 6% |
Other | 5 | 16% |
Unknown | 9 | 28% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 8 | 25% |
Agricultural and Biological Sciences | 5 | 16% |
Psychology | 3 | 9% |
Nursing and Health Professions | 2 | 6% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
Other | 0 | 0% |
Unknown | 12 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 November 2013.
All research outputs
#16,721,717
of 25,374,647 outputs
Outputs from Neuropsychiatric Disease and Treatment
#1,719
of 3,132 outputs
Outputs of similar age
#133,236
of 219,852 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#30
of 60 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,132 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one is in the 39th percentile – i.e., 39% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 219,852 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 60 others from the same source and published within six weeks on either side of this one. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.